

IN THE CLAIMS

1-34. (Canceled)

35. (New) An isolated, synthetic or recombinant χ -conotoxin peptide having the ability to inhibit a neuronal amine transporter, wherein said χ -conotoxin peptide is selected from MrIA as set forth in SEQ ID NO: 1 (NGVCCGYKLCHOC), or MrIB as set forth in SEQ ID NO: 2 (VGVCCGYKLCHOC), wherein "O" represents 4-hydroxyproline.

36. (New) An isolated, synthetic or recombinant χ -conotoxin peptide having the ability to inhibit a neuronal amine transporter, wherein said χ -conotoxin peptide is MrIA as set forth in SEQ ID NO: 1 (NGVCCGYKLCHOC), wherein "O" represents 4-hydroxyproline.

37. (New) An isolated, synthetic or recombinant χ -conotoxin peptide having the ability to inhibit a neuronal amine transporter, wherein said χ -conotoxin peptide is MrIB as set forth in SEQ ID NO: 2 (VGVCCGYKLCHOC), wherein "O" represents 4-hydroxyproline.

38. (New) A method for the treatment or control of pain in a mammal comprising administering to the mammal an effective amount of a χ -conotoxin peptide according to any one of claims 35-37.